多肿瘤标志物蛋白芯片检测中铁蛋白在恶性肿瘤中的诊断价值

Clinical significance of serum ferritin within multiple tumor markers for diagnosis of malignancy

目的探讨多肿瘤标志物蛋白芯片中铁蛋白在恶性肿瘤中的诊断价值。方法收集25 076例可供分析的多肿瘤标志物蛋白芯片检测结果,分析铁蛋白在恶性肿瘤组(肿瘤组)、良性病变组(良性粗)和健康体检组(健康组)中的阳性率及各种类型肿瘤患者中的阳性率,以及铁蛋白伴随其他肿瘤标志物阳性在各类型肿瘤患者中的情况。结果肿瘤组铁蛋白阳性率明显高于良性组及健康组(P<0.01),阳性率最高的肿瘤类型为胰腺癌(28.9%)。2 011例铁蛋白阳性肿瘤患者中,伴随阳性率最高的肿瘤标志物为糖类抗原125(CA125),其后依次为癌胚抗原(CEA)和糖类抗原19-9(CA19-9),伴随阳性率分别为46.2%、34.0%和29.4%。铁蛋白伴随CA125阳性最常见于卵巢癌(71.19%),铁蛋白伴随CEA阳性最常见于肠癌(58.12%),铁蛋白伴随CA19-9阳性最常见于胰腺癌(72.73%)。结论多肿瘤标志物中铁蛋白单独升高对判断肿瘤类型意义不大,与其他指标联合检测对肿瘤类型的辅助诊断有一定意义。

Objective To investigate the clinical significance of serum ferritin within multiple tumor markers for diagnosis of malignancy. Methods The measurement results of serum ferritin collected from 25 076 cases were analyzed. The positive rates of serum ferritin in malignant tumor patients, benign disease patients and health examinations were compared,and combination with other tumor markers of protein chip were further analyzed. Results The positive rate of serum ferritin in patients with malignant tumors was significantly higher than in benign disease patients and health examinations（P〈0.01）. The positive rate of serum ferritin in pancreatic cancer was highest （28. 9%）. The most common positive tumor marker accompanied with serum ferritin was CA125（46.2%） ,followed by CEA（34.0%） and CA19-9（29.4%）. Conclusion The positive serum ferritin combined with other tumor markers of protein chip may help to improve the diagnosis of malignancy.